4547:TYO
Kissei Pharmaceutical Co Ltd
JP¥3,830.00
arrow_upward
+1.59%(+60.00) 1D
ኖቬም 12, 3:30:00 ከሰዓት ጂ ኤም ቲ+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
JP¥3,790
High
JP¥3,835
Low
JP¥3,775
Mkt. cap
178.26 ቢ
Avg. vol.
87.26 ሺ
Volume
71.20 ሺ
Dividend
3.26%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.20
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
Open
JP¥3,790
High
JP¥3,835
Low
JP¥3,775
Mkt. cap
178.26 ቢ
Avg. vol.
87.26 ሺ
Volume
71.20 ሺ
Dividend
3.26%
Quarterly dividend
JP¥31
Ex-dividend date
30 ማርች 2027
P/E ratio
14.20
52-wk high
JP¥5,040
52-wk low
JP¥3,500
EPS
JP¥270
Shares outstanding
46.72 ሚ
No. of employees
2 ሺ
News stories
From web sources and news partners
TradingView
·
ከ1 ሰዓት በፊት
Stock Market Today: Nvidia Rout Sinks Nasdaq, S&P 500 Futures as Board Weighs Jensen Huang’s Future — CRWV, TTEK, FNV in Focus
Yahoo Finance
·
ከ51 ደቂቃዎች በፊት
What SPDR S&P 500 ETF (SPY) Bought: Apple Leads on Nov. 10
BigGo Finance
·
ከ1 ሰዓት በፊት
S&P 500 Has Risen After All 19 Midterm Elections Since 1950, Morgan Stanley Data Show
FXStreet
·
ከ3 ሰዓቶች በፊት
S&P 500: Tech rally offsets post‑CPI selloff – Deutsche Bank
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1.79 ሺ
Founded9 ኦገስ 1946
HeadquartersMatsumoto, Nagano, ጃፓን
SectorHealth Care
IndustryPharmaceutical industry
Websitekissei.co.jp